Metformin

Metformin, the active ingredient in Metformin, is a biguanide presented as an oral tablet for oral use. It reduces hepatic glucose production, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity, making it a cornerstone therapy for adults with type 2 diabetes mellitus and for certain patients with impaired glucose tolerance.

GNH USA supplies Metformin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality compliance with EU standards.

Metformin is indicated for conditions affecting glucose metabolism, primarily within the type 2 diabetes therapeutic pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose. - Prediabetes (impaired fasting glucose or impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle modification. - Polycystic ovary syndrome (adjunct therapy): helps reduce insulin resistance and may improve menstrual regularity.

Metformin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste: transient alteration in taste perception. - Decreased vitamin B12 levels: may develop with long‑term therapy. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe hypoglycemia: usually when combined with insulin or sulfonylureas. - Hepatotoxicity: rare liver injury presenting with elevated enzymes.

When prescribing Metformin, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess creatinine clearance before initiation and periodically during therapy. - Hepatic impairment: avoid use in patients with significant liver disease due to lactic acidosis risk. - Contrast imaging: discontinue metformin before iodinated contrast procedures and restart after renal function is confirmed. - Elderly patients: start at lower doses and monitor for accumulation. - Concomitant alcohol: advise patients to limit alcohol intake to reduce lactic acidosis risk. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metformin’s pharmacokinetic profile leads to several clinically relevant drug interactions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk; discontinue metformin before and after the procedure. - Cimetidine: can increase metformin plasma concentrations, raising the risk of toxicity. - Nitrates (e.g., nitroglycerin): may potentiate hypotensive effects when combined with metformin‑induced vasodilation.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function as combined effect may impair clearance. - Diuretics (especially thiazides): may affect electrolyte balance and renal function. - Beta‑blockers: may mask hypoglycemia symptoms when metformin is used with insulin secretagogues. - Oral corticosteroids: can increase blood glucose, requiring dose adjustments.